Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
Year: 2015
Type: conference-abstract
Source: Cancer Research
Institutions: Memorial Sloan Kettering Cancer Center, King's College London, Vall d'Hebron Hospital Universitari, Solti, Sheba Medical Center, Dana-Farber Cancer Institute, Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, Stanford Medicine, Stanford University, University of Kansas Medical Center, AstraZeneca (United Kingdom), German Breast Group
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1620864007